Page 1

23 November 2021 ArborGen HOLDINGS- ArborGen Holdings Half Year Results Unaudited Results for the Six Months to 30 September 2021 ( 1H FY22 ) All dollar values in US dollars unless otherwise stated ■ ■ ArborGen continues to make progress in markets with identified growth potential ( the US and Brazil ) and remains on track to deliver its highest MCP sales year to date in the US . Agreement for the sale of ArborGen's New Zealand and Australian business ( ANZ business ) for $ 22.25m is now unconditional with completion scheduled for 30 November 2021. Proceeds will afford ArborGen greater strategic and financial flexibility , strengthening our balance sheet so the company can pursue growth opportunities . Positive uplift in revenue for continuing operations ( excluding the ANZ business ) and operating earnings¹of $ 0.6m ( in line with pcp ) , with consolidated net loss of $ 0.5m reflecting inventory adjustment , strategic review and lease termination write - off costs during the period . The company has re - confirmed guidance of US GAAP EBITDA² to be in the range of US $ 11.3 to $ 11.7m for the FY22 , subject to any future impact from supply chain and COVID related issues in the US . ArborGen Holdings Limited ( NZX : ARB ) has announced its unaudited results for the six months to 30 September 2021 , reporting a period of positive revenue and earnings growth in its US and Brazil markets . The six - month consolidated result is presented showing the ArborGen's New Zealand and Australian businesses as discontinued . The sale of the ANZ business for $ 22.25m is now unconditional and completion scheduled for 30 November 2021. The proceeds from the sale will afford ArborGen with greater strategic and financial flexibility , strengthening our balance sheet so the company can pursue growth opportunities . ArborGen's core focus remains on growing sales of its higher margin proprietary advanced genetic products ( Mass Control Pollinated ( MCP ) and Varietals ) in the United States and the company is on track to deliver its highest MCP sales year in FY22 , with year - to - date MCP sales orders now at approximately 104 million seedlings , 24 million units higher than the prior year . Further growth of MCP is expected in future years , driven by increased supply from flowers pollinated in FY21 and ongoing maturity of orchards , and increasing adoption from both industrial and private landowner customers . A number of large industrial customers have publicly stated MCP targets ranging from 75 % to 100 % of their plantings as maturing stands of MCP trees demonstrate compelling value gains , with a much 1 Earnings before other significant items - these comprise government grant subsidies of $ 0.9 million , and one - off expenses relating to tenant eviction and accelerated upfront tenancy costs written off of $ 0.5 million , Brazil inventory adjustment $ 0.2 million , and Strategic Review costs of $ 0.7 million . Other significant items in the prior period comprised $ 2.3 million of government grant subsidies . 2 US GAAP EBITDA excludes NZ public company costs and the Strategic Review costs .